European Companies Search Engine
EU funding (€2,999,266): DESIGN STUDY FOR A EUROPEAN INFRASTRUCTURE ON ADVANCED GENOMICS TECHNOLOGIES Hor18 Oct 2024 EU Research and Innovation programme "Horizon"
Overview
Text
DESIGN STUDY FOR A EUROPEAN INFRASTRUCTURE ON ADVANCED GENOMICS TECHNOLOGIES
Innovation in the genomics field is extremely intense and requires high up-front investments. The toolbox of sequencing platforms with unique features that require specialized training and leverage extensive cross-functional expertise, is rapidly expanding. The EASIGEN-DS project evolves from two EU infrastructure projects that have proven to be very successful in providing access to cutting-edge DNA sequencing technologies to hundreds of researchers. Here, we propose to carry out a design study for establishing a new European Research Infrastructure on Advanced Genomics Technologies, EASIGEN. In order to develop an excellent scientific, technological and operational design, we will conduct landscape studies, stakeholder consultations, and community surveying. In parallel, we will seek for the support and commitment of several national and EU stakeholders and user communities through a multi‐faceted dissemination plan. We envision that EASIGEN will encompass: 1) a Technology Platform that will offer state-of-the-art genomic analysis methods, such as single-cell genomics, spatial genomics and long-read sequencing, as well as population-scale genomics capacity; and 2) a Support Platform that will provide standardization tools, training, co-innovation with industry, and consulting for smaller facilities, including those in widening countries. Both platforms will serve a vast community of users from the health, biomedical and life science fields. The consortium brings together 1) a network of eleven genomics facilities with distinct application specialities. and an aggregated sequencing capacity of >450,000 human genomes per year; 2) four partners with specific and crucial expertise: data stewardship, ethical, legal and social implications, socio-economic impact and innovation. The new infrastructure will strengthen the European Research Area, promote interconnections within the ESFRI landscape, and boost an innovative biotechnology-based industry.
Funded Companies:
| Company name | Funding amount |
| Deutsches Krebsforschungszentrum Heidelberg | ? |
| Charite - Universitaetsmedizin Berlin | €120,688 |
| Christian-Albrechts-Universitaet ZU Kiel | €0.00 |
| Commissariat a L Energie Atomique et aux Energies Alternatives | €158,225 |
| Consorcio para La Explotacion del Centro Nacional de Analisis Genomico | €649,041 |
| Csil SCRL | €327,063 |
| Fraunhofer Gesellschaft ZUR Forderung DER Angewandten Forschung e. V. | €266,188 |
| Fundacio Centre de Regulacio Genomica | €86,344 |
| Katholieke Universiteit Leuven | €410,875 |
| Kungliga Tekniska Hoegskolan | €391,550 |
| Ruder Boskovic Institute | €67,688 |
| Tartu Ulikool | €74,088 |
| Universitatsklinikum Schleswig-Holstein | €359,925 |
| Universite de Toulouse | €87,594 |
Source: https://cordis.europa.eu/project/id/101187908
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts, Heidelberg, Germany.
